Although the VEGF signaling pathway has been previously investigated as a potential EGFR‐TKI resistance pathway,5, 6, 7 it remains unclear whether the expression level of the VEGF‐ligand or VEGFR‐receptor could predict the outcome after EGFR‐TKI monotherapy in advanced EGFR‐mutated NSCLC. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.